TriangleCognitive Assessment (NCT06175000)
Cognitive Assessment trial for Primary Central Nervous System Lymphoma (NCT06175000). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with CD20-positive primary central nervous system lymphoma that partly or completely responded to first-line high-dose methotrexate treatment. Enrollment must follow treatment within seventy-five days; previous eye or spinal-fluid involvement must have cleared.
The idea: compare maintenance obinutuzumab infusions with observation for two years. Obinutuzumab binds CD20 on lymphoma cells and promotes immune-mediated killing. Treatment cycles repeat every sixty days. Researchers measure how long responses last and assess thinking and quality of life.
This phase 2 study plans 28 patients. Providence's Prakash Ambady leads six recruiting US sites.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.